Omeros
About OmerosPipelineInvestorsNews


2014 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle  
06/02/14Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures
-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE, June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no post-marketing commi... 
 Printer Friendly Version
05/12/14Omeros Corporation Reports First Quarter 2014 Financial Results
-- Secures Additional $50.4 Million in Cash in 1Q 2014 -- SEATTLE, May 12, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the first quarter of 2014, which include: 1Q 2014 net loss of $16.6 million, ... 
 Printer Friendly Version
04/07/14Omeros to Present at the 13th Annual Needham Healthcare Conference
SEATTLE, April 7, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference in New York later this week.  The presentation is scheduled for Wednesday, April 9, 2014 at 3:00 p.m. ED... 
 Printer Friendly Version
04/03/14Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key r... 
 Printer Friendly Version
04/01/14Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference
-- Conference Focuses on New Drug Development and Cutting Edge Research in Schizophrenia -- SEATTLE, April 1, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) to make an oral presentation on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. OMS824 se... 
 Printer Friendly Version
03/21/14Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference
SEATTLE, March 21, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BioCentury Future Leaders in the Biotech Industry Conference in New York next week.  The presentation is scheduled for Friday, March 28, 2014 at ... 
 Printer Friendly Version
03/19/14Omeros Closes $40.25 Million Public Offering of Common Stock
SEATTLE, March 19, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on March 14, 2014, relating to the sale of 3,500,000 shares of its common stock at a price of $11.50 per share for gross proceeds of approximately $40.25 million. The closing included the sale of 456,521 shares of common stock sold pursuant to the overallotment option granted by ... 
 Printer Friendly Version
03/14/14Omeros Prices $35.0 Million Public Offering of Common Stock
SEATTLE, March 14, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 3,043,479 shares of its common stock at a price to the public of $11.50 per share for gross proceeds of $35.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $32.8 million. Omeros has also granted the underwriters a 30-day option to purcha... 
 Printer Friendly Version
03/13/14Omeros Announces Proposed Public Offering of Common Stock
SEATTLE, March 13, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any. Omeros intends to use the net proceeds of the offering for gene... 
 Printer Friendly Version
03/13/14Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results
-- 4Q 2013 net loss of $1.8 million, or $0.05 per share -- SEATTLE, March 13, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the fourth quarter and year ended December 31, 2013, which include: 4Q 201... 
 Printer Friendly Version
03/10/14Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE, March 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA).  TMAs are ... 
 Printer Friendly Version
03/06/14Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the previously repor... 
 Printer Friendly Version
03/05/14Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds
SEATTLE, March 5, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which is expected to fund later today. The new credit facility consists of a $32 million term loan, which requires interest-only payments through March 2015. Thereafter, monthly principal and interest payments will be due through the March 2018 maturity date. The company will use a portion of the loan proceeds to repay its ... 
 Printer Friendly Version
03/04/14Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program
-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE, March 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulato... 
 Printer Friendly Version
02/26/14Omeros to Present at Cowen and Company 34th Annual Health Care Conference
SEATTLE, Feb. 26, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference in Boston, Massachusetts next week.  The presentation is scheduled for Wednesday, ... 
 Printer Friendly Version
02/19/14Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE, Feb. 19, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a bat... 
 Printer Friendly Version
02/11/14Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses -- SEATTLE, Feb. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the la... 
 Printer Friendly Version
02/05/14FDA Grants Fast Track Designation to Omeros' OMS824 Huntington's Disease Program
-- Enrollment in Huntington's Phase 2 Trial Expected Soon -- SEATTLE, Feb. 5, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, for the treatment of cognitive impairment in patients with Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affec... 
 Printer Friendly Version
02/03/14Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721
-- Phase 2 Program Expected to Initiate this Quarter -- SEATTLE, Feb. 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data following completion of dosing in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. OMS721, administered either by subcutaneous injection or intravenous infusion, was well tol... 
 Printer Friendly Version
01/29/14Omeros Reports Positive Results from OMS824 Phase 2a Clinical Trial
- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE, Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizo... 
 Printer Friendly Version